Breaking News Instant updates and real-time market news.

KIN

Kindred Biosciences

$6.95

-0.05 (-0.71%)

07:20
06/16/17
06/16
07:20
06/16/17
07:20

Kindred Biosciences initiated with a Buy at Aegis

Aegis analyst Benjamin Haynor initiated Kindred with a Buy and a $10.50 price target to reflect upcoming approvals and a deep pipeline. The analyst said Kindred has two veterinary therapeutics before the FDA, Mirataz and Zimeta, both have received clearances on the efficacy portions of the NADA filing an expects approval and launch by year end.

KIN Kindred Biosciences
$6.95

-0.05 (-0.71%)

05/24/17
05/24/17
INITIATION
Target $10

Outperform
Kindred Biosciences initiated with an Outperform at FBR Capital
FBR Capital analyst Edward White started Kindred Biosciences with an Outperform rating and $10 price target.
01/03/17
FLTL
01/03/17
INITIATION
Target $9.25
FLTL
Strong Buy
Kindred Biosciences initiated with a Strong Buy at Feltl
Feltl initiated Kindred Biosciences with a Strong Buy and a $9.25 price target.
11/01/16
LTCO
11/01/16
INITIATION
Target $7.5
LTCO
Buy
Kindred Biosciences initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter started Kindred Biosciences with a Buy rating and $7.50 price target. The analyst views Kindred "as an emerging leader in development of new biologic therapies for companion animals with two potential product launches in 2017."

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.